Indaptus Therapeutics, Inc. (INDP) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Indaptus Therapeutics, Inc. (INDP) Bundle
Simplify Indaptus Therapeutics, Inc. (INDP) valuation with this customizable DCF Calculator! Featuring real Indaptus financials and adjustable forecast inputs, you can test scenarios and uncover Indaptus fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -46.1 | -3.6 | -7.7 | -14.9 | -16.4 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .9 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -46.9 | -3.6 | -7.7 | -14.9 | -16.4 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 10.1 | 1.6 | 39.1 | 26.4 | 13.4 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 3.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .0 | .2 | 2.5 | 1.4 | .8 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -.9 | .0 | .0 | -.2 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -47.6 | -3.6 | -7.7 | -14.3 | -16.4 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -51.1 | .0 | -5.4 | -15.6 | -16.9 | -.8 | .0 | .0 | .0 | .0 |
WACC, % | 9.66 | 9.66 | 9.66 | 9.65 | 9.66 | 9.66 | 9.66 | 9.66 | 9.66 | 9.66 |
PV UFCF | ||||||||||
SUM PV UFCF | -.7 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -13 | |||||||||
Equity Value | 12 | |||||||||
Diluted Shares Outstanding, MM | 8 | |||||||||
Equity Value Per Share | 1.48 |
What You Will Receive
- Customizable Excel Template: A fully adaptable Excel-based DCF Calculator featuring pre-filled financial data for Indaptus Therapeutics, Inc. (INDP).
- Comprehensive Data: Historical performance data and forward-looking projections (as indicated in the highlighted cells).
- Flexible Forecasting: Modify forecast parameters such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs affect the valuation of Indaptus Therapeutics, Inc. (INDP).
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and user-friendliness, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life INDP Financials: Pre-filled historical and projected data for Indaptus Therapeutics, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Indaptus’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Indaptus’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Indaptus Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Indaptus Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Indaptus Therapeutics, Inc. (INDP) Calculator?
- User-Friendly Interface: Tailored for both novice users and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your specific analysis needs.
- Real-Time Feedback: Observe immediate updates to Indaptus's valuation as you change inputs.
- Preloaded Data: Comes with Indaptus's latest financial metrics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply theoretical knowledge to real-world scenarios.
- Researchers: Utilize advanced models in their studies related to therapeutic innovations.
- Investors: Evaluate your investment strategies and analyze valuation metrics for Indaptus Therapeutics, Inc. (INDP).
- Market Analysts: Enhance your analysis with a customizable model tailored for biotech evaluations.
- Healthcare Entrepreneurs: Understand how emerging biotech companies like Indaptus Therapeutics, Inc. (INDP) are assessed in the market.
What the Template Contains
- Pre-Filled Data: Includes Indaptus Therapeutics, Inc.'s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Indaptus Therapeutics, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.